Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Therapeutics save search
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
CALT | $18.3 -2.35% 4.5K
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
nephropathy congress world nefecon trial therapeutics
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE 4 | $42.05 1.08% 700K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Published: 2024-04-17 (Crawled : 22:00) - biospace.com/
DMAC | News | $2.6 14K
|
Health Technology
|
| O: 4.43%
H: 0.0%
C: 0.0%
dm199 first stroke treatment for trial therapeutics
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $122.675 -1.49% 2.1M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.16 4.69% 1M
|
Health Technology
|
| O: -15.02%
H: 3.55%
C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5195 3.59% 260K
|
Professional, Scientific, and T...
|
| O: 0.11%
H: 5.95%
C: -13.78%
mc138 fda ttx-mc138 tumors clearance trial therapeutics advanced
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.91 -2.8% 71K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
BTAI | $2.605 0.58% 180K
|
Health Technology
|
| O: 0.96%
H: 1.9%
C: 0.0%
bxcl501 alzheimer’s dementia for trial therapeutics
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
BCLI | $0.497 -8.1% 770K
|
Health Technology
|
| O: -20.14%
H: 0.0%
C: 0.0%
als biomarker publication cell trial therapeutics
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.97 -0.87% 420K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.445 7.04% 1.9M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
MCRB | $0.5992 -4.48% 2.4M
|
Health Technology
|
| O: -2.31%
H: 3.86%
C: -1.47%
ser-155 for trial therapeutics
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI | $0.497 -8.1% 770K
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
EFTR | $1.88 -0.53% 78K
|
|
| O: -76.55%
H: 13.89%
C: -17.78%
lung cancer cell topline trial therapeutics results
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.654 1.85% 190K
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.615 3.22% 560K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ADCT | $4.74 -4.44% 150K
|
Health Technology
|
| O: 0.68%
H: 11.71%
C: 6.08%
zynlonta trial therapeutics
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.815 0.06% 160K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Published: 2024-04-03 (Crawled : 13:00) - biospace.com/
ALGS | $0.7988 1.5% 180K
|
Health Technology
|
| O: 2.25%
H: 4.0%
C: 1.0%
alg-0550 first therapeutics study
Gainers vs Losers
| 68% | 32% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
XPON | $2.63 36.27% 8.4M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.